Effect of a beta 2-adrenoceptor stimulation on hyperglycemia-induced endothelial dysfunction.
To investigate whether beta(2)-adrenoceptors exist on endothelial cells and whether a beta(2)-adrenoceptor stimulation might prevent the development of hyperglycemia-induced endothelial dysfunction, porcine aortic endothelial cells (PAECs) were cultured and chronically exposed to either 5 mM D-glucose ("normoglycemia") or 20 mM D-glucose ("hyperglycemia"), with or without 100 nM salbutamol in absence or presence of beta(2)-adrenoceptor antagonist ICI 118,551 [1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxyl]-3-[(1-methylethyl)-amino]-2-butanol] or beta(1)-antagonist metoprolol. For osmotic control, PAECs were exposed to 15 mM L-glucose. We measured nitric oxide release using the met-hemoglobin assay and assessed beta-adrenoceptor density and subtypes by radioligand binding. Furthermore, we determined intracellular NADH and NADPH using high-performance liquid chromatography. High D-glucose concentrations but not L-glucose led to significantly reduced basal and stimulated nitric oxide release. Chronic salbutamol treatment significantly antagonized the impairment of the nitric oxide response, which was inhibited by ICI 118,551 but not by metoprolol. The number of giant cells was significantly increased in hyperglycemia, which could be prevented by salbutamol. Binding of the radioligand (-)-[(125)I]iodocyanopindolol revealed a total beta-adrenoceptor density of 29.8 +/- 3.7 (normoglycemic) and 30.3 +/- 3.6 (hyperglycemic) fmol/mg protein. Displacement by ICI 118,551 revealed beta-adrenoceptor subtype distribution with 30.3 +/- 4.4 (normoglycemic) and 29.1 +/- 3.8% beta(2)-adrenoceptors. NADH production increased in hyperglycemia, which was completely prevented by salbutamol. We conclude that hyperglycemia in PAEC induces endothelial dysfunction with impaired nitric oxide release and that this can be prevented by beta(2)-adrenoceptor stimulation.
Kabat
Armin
A
Institute for Pharmacology, University of Halle, Germany.
Pönicke
Klaus
K
Salameh
Aida
A
Mohr
Friedrich-Wilhelm
FW
Dhein
Stefan
S
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D015726:Giant Cells / Q000187:drug effects; D006943:Hyperglycemia / Q000150:complications / Q000201:enzymology / Q000473:pathology*; D009252:NADPH Dehydrogenase / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D009711:Nucleotides / Q000378:metabolism; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism*; D013552:Swine; D014652:Vascular Diseases / Q000209:etiology / Q000473:pathology
D000318:Adrenergic beta-Agonists; D009711:Nucleotides; D018343:Receptors, Adrenergic, beta-2; D009569:Nitric Oxide; D009252:NADPH Dehydrogenase